What question did this study set out to answer?

This systematic review aims to analyze adverse events associated with bedaquiline-pretomanid regimens for drug-resistant tuberculosis.

Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies

View Full Paper

Ask AI

Bookmark

Authors

Systematic review analyzes adverse events in drug-resistant tuberculosis treatments, indicating critical safety insights for patient management.

This systematic review aims to analyze adverse events associated with bedaquiline-pretomanid regimens for drug-resistant tuberculosis.
Conducted a systematic review of 14 studies including seven clinical trials, six implementation studies, and one pharmacovigilance study.
Performed a search through PubMed, Medline, and Web of Science for studies reporting adverse event data.
Compared methods of adverse event detection between clinical trials and implementation studies.
Adverse event prevalence was higher in clinical trials (62.2-100%) compared to implementation studies (41.8-72.8%).
Serious adverse events occurred in 2.2-30.2% of patients, with 7.7-54.3% needing drug interruption.
79.2% of patients showed full recovery from adverse events, yet 23-32% reported ongoing adverse events post-treatment.

Maria et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review analyzes adverse events in drug-resistant tuberculosis treatments, indicating critical safety insights for patient management.